Maxigen Biotech Inc. (1783.TW)
TWD 43.3
(-0.12%)
TWD 43.3
(-0.12%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 622.11 Million TWD | 2.93% |
| 2022 | 604.43 Million TWD | 18.06% |
| 2021 | 511.97 Million TWD | 11.86% |
| 2020 | 457.69 Million TWD | 1.21% |
| 2019 | 452.19 Million TWD | 5.73% |
| 2018 | 427.68 Million TWD | 0.03% |
| 2017 | 427.56 Million TWD | 27.1% |
| 2016 | 336.38 Million TWD | 28.65% |
| 2015 | 261.46 Million TWD | 6.42% |
| 2014 | 245.68 Million TWD | 5.47% |
| 2013 | 232.94 Million TWD | 4.93% |
| 2012 | 221.99 Million TWD | 24.11% |
| 2011 | 178.87 Million TWD | 3.73% |
| 2010 | 172.44 Million TWD | -4.52% |
| 2009 | 180.6 Million TWD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 127.05 Million TWD | -14.58% |
| 2024 Q2 | 174.01 Million TWD | 36.96% |
| 2023 Q3 | 159.42 Million TWD | -6.72% |
| 2023 Q1 | 143.02 Million TWD | -12.95% |
| 2023 Q2 | 170.91 Million TWD | 19.5% |
| 2023 FY | 622.11 Million TWD | 2.93% |
| 2023 Q4 | 148.74 Million TWD | -6.7% |
| 2022 Q3 | 162.63 Million TWD | 5.45% |
| 2022 Q1 | 123.26 Million TWD | -12.78% |
| 2022 FY | 604.43 Million TWD | 18.06% |
| 2022 Q4 | 164.3 Million TWD | 1.03% |
| 2022 Q2 | 154.22 Million TWD | 25.12% |
| 2021 Q2 | 121.07 Million TWD | 9.07% |
| 2021 Q4 | 141.32 Million TWD | 1.99% |
| 2021 Q1 | 111 Million TWD | -9.69% |
| 2021 FY | 511.97 Million TWD | 11.86% |
| 2021 Q3 | 138.56 Million TWD | 14.45% |
| 2020 Q4 | 122.92 Million TWD | 6.82% |
| 2020 Q1 | 103.32 Million TWD | -7.62% |
| 2020 Q2 | 116.37 Million TWD | 12.62% |
| 2020 Q3 | 115.07 Million TWD | -1.11% |
| 2020 FY | 457.69 Million TWD | 1.21% |
| 2019 Q4 | 111.85 Million TWD | -7.29% |
| 2019 Q3 | 120.64 Million TWD | -5.35% |
| 2019 FY | 452.19 Million TWD | 5.73% |
| 2019 Q1 | 92.23 Million TWD | -1.93% |
| 2019 Q2 | 127.46 Million TWD | 38.19% |
| 2018 Q3 | 113.07 Million TWD | -0.9% |
| 2018 Q2 | 114.1 Million TWD | 7.21% |
| 2018 Q4 | 94.05 Million TWD | -16.82% |
| 2018 FY | 427.68 Million TWD | 0.03% |
| 2018 Q1 | 106.43 Million TWD | -4.42% |
| 2017 Q2 | 117.86 Million TWD | 27.19% |
| 2017 FY | 427.56 Million TWD | 27.1% |
| 2017 Q3 | 105.66 Million TWD | -10.35% |
| 2017 Q1 | 92.66 Million TWD | -11.22% |
| 2017 Q4 | 111.36 Million TWD | 5.39% |
| 2016 Q4 | 104.38 Million TWD | 18.49% |
| 2016 Q2 | 80.56 Million TWD | 27.2% |
| 2016 Q1 | 63.34 Million TWD | -1.8% |
| 2016 Q3 | 88.09 Million TWD | 9.35% |
| 2016 FY | 336.38 Million TWD | 28.65% |
| 2015 Q1 | 55.73 Million TWD | 2.9% |
| 2015 Q2 | 74.11 Million TWD | 32.96% |
| 2015 Q3 | 67.11 Million TWD | -9.44% |
| 2015 Q4 | 64.5 Million TWD | -3.9% |
| 2015 FY | 261.46 Million TWD | 6.42% |
| 2014 FY | 245.68 Million TWD | 5.47% |
| 2014 Q2 | 67.38 Million TWD | 10.37% |
| 2014 Q1 | 61.05 Million TWD | -4.99% |
| 2014 Q4 | 54.16 Million TWD | -14.12% |
| 2014 Q3 | 63.07 Million TWD | -6.4% |
| 2013 Q1 | 50.28 Million TWD | 2.49% |
| 2013 Q3 | 54.79 Million TWD | -13.87% |
| 2013 Q4 | 64.26 Million TWD | 17.29% |
| 2013 FY | 232.94 Million TWD | 4.93% |
| 2013 Q2 | 63.61 Million TWD | 26.51% |
| 2012 Q2 | - TWD | 0.0% |
| 2012 Q4 | 49.06 Million TWD | -13.0% |
| 2012 Q3 | 56.39 Million TWD | 0.0% |
| 2012 FY | 221.99 Million TWD | 24.11% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 FY | 178.87 Million TWD | 3.73% |
| 2011 Q2 | - TWD | 0.0% |
| 2010 FY | 172.44 Million TWD | -4.52% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | 180.6 Million TWD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 2.15 Billion TWD | 71.067% |
| SciVision Biotech Inc. | 712.98 Million TWD | 12.745% |
| Bionime Corporation | 1.75 Billion TWD | 64.563% |
| Pegavision Corporation | 6.78 Billion TWD | 90.838% |
| Visco Vision Inc. | 2.39 Billion TWD | 74.053% |